Pricing and reimbursement of biosimilars in central and Eastern European countries

Frontiers in Pharmacology

Volumn 8, Issue JUN, 2017, Pages

  Kawalec, Pawel ^a   Stawowczyk, Ewa ^a   Tesar, Tomas ^b   Skoupa, Jana ^c   Turcu Stiolica, Adina ^d   Dimitrova, Maria ^e   Petrova, Guenka I ^e   Rugaja, Zinta ^f   Männik, Agnes ^g   Harsanyi, Andras ^h,i   Draganic, Pero ^j  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Faculty of Natural Sciences   (Slovakia)

^c Czechta Institute   (Czech Republic)

^d UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^e MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^f Senior Expert at The National Health Service   (Latvia)

^g UNIVERSITY OF TARTU   (Estonia)

^h National Health Insurance Fund   (Hungary)

ⁱ EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^j Agency for Medicinal Products and Medical Devices   (Croatia)

more..

Author keywords

Biosimilar pharmaceuticals; Interchangeability; Original products; Pricing; Reimbursement

Indexed keywords

ADALIMUMAB; BETA1A INTERFERON; BEVACIZUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; FILGRASTIM; HUMAN GROWTH HORMONE; INFLIXIMAB; INSULIN ASPART; INSULIN GLARGINE; NATALIZUMAB; OMALIZUMAB; PARATHYROID HORMONE[1-34]; PEGFILGRASTIM; RANIBIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RITUXIMAB; TRASTUZUMAB;

ARTICLE; BULGARIA; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CROATIA; CZECH REPUBLIC; DRUG COST; DRUG MARKETING; ESTONIA; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE FINANCING; HUMAN; HUNGARY; LATVIA; LITHUANIA; POLAND; QUESTIONNAIRE; REIMBURSEMENT; ROMANIA; SLOVAKIA; STANDARD;

EID: 85020722141     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00288     Document Type: Article

References (25)

1. Brodszky, V., Gulacsi, L., Balogh, O., Baji, P., Rencz, F., and Péntek, M. (2014). Budget impact analysis of biosimilar infliximab for the treatment of crohn's disease in six central eastern European countries. Value Health 17:A364. doi: 10.1016/j.jval.2014.08.805
2. Brodszky, V., Rencz, F., Péntek, M., Baji, P., Lakatos, P. L., and Gulácsi, L. (2016). A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev. Pharmacoecon. Outcomes Res. 16, 119-125. doi: 10.1586/14737167.2015.1067142
3. Derbyshire, M. (2015). Patent expiry dates for best-selling biological. Gene. Biosimilars Initiat. J. 4, 178-179. doi: 10.5639/gabij.2015.0404.040
4. ESzCsM Decree (2017). 32/2004. (IV. 26.) ESzCsM Decree, Concerning the Reimbursement of Medicinal Products. Available online at: http://net.jogtar.hu/jr/gen/hjegy_doc.cgi?docid=A0400032.ESC (Accessed February 13, 2017)
5. European Medicines Agency (2017). European Public Assessment Reports. Available online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit (Accessed February 13, 2017)
6. Grabowski, H., Guha, R., and Salgado, M. (2014). Biosimilar competition: lessons from Europe. Nat. Rev. Drug Discov. 13, 99-100. doi: 10.1038/nrd4210
7. Hornyák, L., Nagy, Z., Tálos, Z., Endrei, D., ágoston, I., Csákvári, T., et al. (2014). Experiences with price competition of biosimilar drugs in Hungary. Acta Pharm. Hung. 84, 83-87. doi: 10.1016/j.jval.2014.08.1018
8. Hornyák, L., Nagy, Z., Tálos, Z., Endrei, D., ágoston, I., Csákvári, T., et al. (2015). Experiences with price competition of biosimilar drugs in hungary in case of colony-stimulating factor products. Value Health 18:A477. doi: 10.1016/j.jval.2015.09.1285
9. IMS (2016). Delivering on the Potential of Biosimilar Medicines. The Role of Functioning Competitive Markets. IMS Institute for Healthcare Informatics. Available online at: http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdf (Accessed February 13, 2017)
10. Jakovljevic, M. B. (2014). Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia Health Econ. Ther. Pathways 15, 27-32. doi: 10.7175/fe.v15i1.909
11. Kawalec, P., and Malinowski, K. P. (2016). Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis. Health Policy 120, 1240-1248. doi: 10.1016/j.healthpol.2016.09.021
12. Long, D. (2015). "Perspective on the evolving biosimilars landscape," in HDMA Distribution Management Conference and EXPO (Orlando, FL)
13. Ministry of Health (2011). [Decree No. 422/2011 of the Ministry of Health of the Slovak Republic on the Details of the Pharmacoeconomic Analysis of Medicine] Vyhláškac. 422/2011 MZ SR o Podrobnostiach Farmako-Ekonomického Rozboru Lieku. Available online at: http://www.zakonypreludi.sk/zz/2011-422
14. Ministry of Health (2013). Ministry of Health Order No. 724/2013 Regarding the Approval of Criteria for Evaluation of Medical Technologies, the Documents to be Submitted by Applicants, the Process and the Methodology Used to Assess the Drugs, and the New Indications to be Included on the Reimbursement List. Bucarest: Romanian Official Gazette No. 339 (Accessed June 10, 2013)
15. Ministry of Health (2014). Ministry of Health Order No. 861/2014 (BC 17.03.2015) Regarding the Approval of Criteria for Evaluation of Medical Technologies, the Documents to be Submitted by Applicants, the Process and the Methodology Used to Assess the Drugs, the New Indications to be Included on the Reimbursement List, and the Criteria for Exclusion of Drugs from the List. Bucarest: Romanian Official Gazette No. 557. (Accessed July 28, 2014)
16. Ministry of Health (2015a). Ministry of Health Order No. 1505/29.12.2015 Regarding the Modification of National Health Insurance House Order No. 944/2015. Bucarest: Ministry of Health
17. Ministry of Health (2015b). 1750/30.12.2015 and National Health Insurance House Order No. 1506/29.12.2015 Regarding the Approval of the Calculation, the List of Trade Names and Prices of Drugs for Patients in National Health Programs and the Methodology for their Calculation. Ministry of Health
18. Mulcahy, A. W., Predmore, Z., and Mattke, S. (2014). The Cost Savings Potential of Biosimilar Drugs in the United States. RAND Corporation. Available online at: http://www.rand.org/pubs/perspectives/PE127.html
19. Nagy, Z., Hornyák, L., Tálos, Z., Endrei, D., ágoston, I., Csákvári, T., et al. (2015). Experiences with price competition of biosimilar drugs in Hungary in case of erythropoietin products. Value Health 18:A513. doi: 10.1016/j.jval.2015.09.1485
20. Ornes, S. (2015). Core concepts: biosimilars. Proc. Natl. Acad. Sci. U.S.A. 112, 15261-15262. doi: 10.1073/pnas.1520698112
21. Panteli, D., Arickx, F., Cleemput, I., Dedet, G., Eckhardt, H., Fogarty, E., et al. (2016). Pharmaceutical regulation in 15 European countries review. Health Syst. Transit. 18, 1-122
22. Regulation of Ministry of Social Affairs (2017). Procedure for Drafting and Amendment of a List of Medicinal Products of the Estonian Health Insurance Fund and the Content of Criteria for Establishing the List and Evaluators of Compliance with the Criteria. Available online at: https://www.riigiteataja.ee/en/eli/ee/SOM/reg/516062015002/consolide (Accessed February 13, 2017)
23. Remuzat, C., Dorey, J., Cristeau, O., Ionescu, D., Radière, G., and Toumi, M. (2017). Key drivers for market penetration of biosimilars in Europe. J. Mark. Access Health Policy 5:1272308. doi: 10.1080/20016689.2016.1272308
24. Rovira, J., Lindner, L., Gimenez, E., Espín, J., de Labry, A. O., and García, L. (2013). Biosimilars in the European market. Gene. Biosimilars Init. J. 1, 30-35. doi: 10.5639/gabij.2013.0201.012
25. Vogler, S., Schneider, P., Gombocz, M., and Zimmermann, N. (2016). "Differences in pricing policies for generic and biosimilar medicines," in ISPOR 19th Annual European Congress (Vienna: Scientific Presentation Database). Available online at: www.ispor.org